Article in Oncoimmunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Muhammad Zaeem NomanTumor Immunotherapy and Microenvironment (TIME), Department of Cancer Research, Luxembourg Institute of Health (LIH), Luxembourg City, Luxembourg.
Martyna SzpakowskaImmuno-Pharmacology and Interactomics, Department of Infection and Immunity, Luxembourg Institute of Health (LIH), Esch-sur-Alzette, Luxembourg.ORCID 0000-0002-5659-8377
Malina XiaoTumor Immunotherapy and Microenvironment (TIME), Department of Cancer Research, Luxembourg Institute of Health (LIH), Luxembourg City, Luxembourg.
Ruize GaoTumor Immunotherapy and Microenvironment (TIME), Department of Cancer Research, Luxembourg Institute of Health (LIH), Luxembourg City, Luxembourg.
Kris Van MoerTumor Immunotherapy and Microenvironment (TIME), Department of Cancer Research, Luxembourg Institute of Health (LIH), Luxembourg City, Luxembourg.
Akinchan KumarTumor Immunotherapy and Microenvironment (TIME), Department of Cancer Research, Luxembourg Institute of Health (LIH), Luxembourg City, Luxembourg.
Markus OllertImmuno-Pharmacology and Interactomics, Department of Infection and Immunity, Luxembourg Institute of Health (LIH), Esch-sur-Alzette, Luxembourg.
Guy BerchemTumor Immunotherapy and Microenvironment (TIME), Department of Cancer Research, Luxembourg Institute of Health (LIH), Luxembourg City, Luxembourg.
Andy ChevignéImmuno-Pharmacology and Interactomics, Department of Infection and Immunity, Luxembourg Institute of Health (LIH), Esch-sur-Alzette, Luxembourg.ORCID 0000-0003-4768-6743
Bassam JanjiTumor Immunotherapy and Microenvironment (TIME), Department of Cancer Research, Luxembourg Institute of Health (LIH), Luxembourg City, Luxembourg.ORCID 0000-0002-9763-0943
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Immune checkpoint blockade (ICB) therapies, such as anti-PD-1, have transformed cancer treatment, but many patients do not respond due to a non-inflammatory tumor microenvironment (TME). Here, we investigated the impact of targeting Atypical Chemokine Receptor 2 (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Targeting the atypical chemokine receptor 2 ( · full record | OpenQuestion